Lawrence Flaherty
Position Title
Professor - ClinicalHematology-Oncology
Office Location
Karmanos Cancer Institute4100 John R
Mail Code: HW04HO
Detroit, MI 48201
Office Phone
313-576-8715Education Training
Education
(1974-1978) M.D., St. Louis University School of Medicine
(1970-1974) B.S., University of Notre Dame
Postgraduate Training
(1983-1986) Fellow in Hematology Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA
(1982-1983) Fellow in Hematology Oncology, Mount Sinai Hospital, Milwaukee, WI
(1981-1982) Chief Medical Resident, Medical College of Wisconsin Affiliated Hospitals, Milwaukee, WI
(1979-1981) Resident in Medicine, Medical College of Wisconsin Affiliated Hospitals, Milwaukee, WI
(1978-1979) Intern in Medicine, Medical College of Wisconsin Affiliated Hospitals, Milwaukee, WI
Professional Experience
Faculty Appointments
(1999-Present) Professor, Department of Oncology, Division of Hematology, Wayne State University School of Medicine, Detroit, MI
(1993-1999) Associate Professor, Department of Internal Medicine, Division of Hematology and Oncology, Wayne State University School of Medicine, Detroit, MI
(1986-1992) Assistant Professor, Department of Internal Medicine, Division of Hematology and Oncology, Wayne State University School of Medicine, Detroit, MI
Hospital or Other Professional Appointments
(2003-Present) Melanoma Multidisciplinary Team Leader, Karmanos Cancer Institute
(2003-Present) Medical Director, Clinical Trials Office, Karmanos Cancer Institute
(2000-Present) Member, Karmanos Cancer Institute
(2001-2013) Board of Directors, Michigan Society of Hematology and Oncology
(1995-2011) Acting Associate Director of Clinical Research, Karmanos Cancer Institute
(2001-2005) President of the Detroit Medical Center Institute for Oncology and Allied Disease (DMCIOAD)
(2001-2003) Acting Division Chief, Division of Hematology and Oncology
(1996-1997) Associate Director of Oncology, Division of Hematology and Oncology
(1991-1995) Service Chief, Genito-Urinary, Melanoma, and Biologics Group Division of Medical Oncology
(1988-1992) Medical Oncologist, Multidisciplinary Pigmented Skin Lesion Program
(1986-1995) Medical Director, Oncology Outpatient Practice, Wayne State University, Detroit, MI
(1988-1992) Preceptor, Fellowship Training Program, Division of Hematology and Oncology, Wayne State University, Detroit, MI
(1986-1992) Board of Directors of DMCIOAD (Detroit Medical Center Institute for Oncology and Allied Disease)
Major Professional Societies
Member, ACP (American College of Physicians)
Member, SWOG (Southwest Oncology Group)
Member, ASCO (American Society of Clinical Oncology)
Board Certification
(1986) American Board of Hematology
(1985) American Board of Oncology
(1982) American Board of Internal Medicine
Honors and Awards
(2001-2012) Best Doctors in America
(2010-2012), (2008-2009), (2005-2006) Top Physicians in Detroit-Hour Detroit Magazine
(2006) Wayne State University -20 year Service Award
(2006) Heroes in Breast Cancer-Detroit
(2004) Wayne State University College Teaching Awarded
(2001) Wayne State University 15 year Service Award
(2000) Karmanos Cancer Institute President's Achievement Award in Clinical Services
(1999) Wayne State University-Leadership and Teaching in CME Award
(1999) Wayne State University-Outstanding Teaching Award
(1998) Karmanos Cancer Institute Performance Recognition Award
(1998) Wayne State University, Outstanding teaching Award,
(1998) Karmanos Cancer Institute-Performance Recognition Award
(1997) Wayne State University, Outstanding teaching Award
(1985-1986) Fellow of the American Cancer Society
(1978) Distinguished Service Award, St. Louis University School of Medicine
(1997-1978) Representative, Educational Policy Committee, St. Louis University School of Medicine
Courses taught
Medical Resident Instruction
Research Interests
Breast Cancer and Melanoma Clinical Trials
Publications
Flaherty KT, Lee SJ, Zhao F, Schuchter LM, Flaherty L, Kefford R, Atkins MB, Leming P, Kirkwood JM. Phase III Trial of Carboplatin and Paclitaxel With or Without Sorafenib in Metastatic Melanoma. J Clin Oncol. 2013 Jan 20;31(3):373-9. doi: 10.1200/JCO.2012.42.1529. Epub 2012 Dec 17. PMID: 23248256 [PubMed-in process]
Margolin KA, Moon J, Flaherty LE, Lao CD, Akerley WL 3rd, Othus M, Sosman JA, Kirkwood JM, Sondak VK. Randomized Phase II Trial of Sorafenib with Temsiroliumus or Tipifarnib in Untreated Metastatic Melanoma (SWOG S0438). Clin Cancer Res 2012 Jan 6 [Epub ahead of print] PMID: 22228638
Gartner EM, Silverman P, Simon M, Flaherty L, Abrams J, Ivy P, LoRusso PM. A Phase II Study of 17-allylamino-17-Demethoxygeldanamycin In Metastatic or Locally Advanced, Unresectable Breast Cancer. Breast Cancer Res Treat 2011 [Epub ahead of print] PMID: 22083229
Livingston RB, Barlow WE, Kash JJ, Albain KS, Gralow JR, Lew DL, Flaherty LE, Royce ME, Hortobagyi GN. SWOG S0215: A Phase II Study of Docetaxel and Vinorelbine Plus Filgrastim With Weekly Trastuzumab for HER2-Positive, Stage IV Breast Cancer. Breast Cancer Res Treat 130(1):123-31, 2011. PMID: 21826527
Sosman A, Moon J, Tuthill RJ, Warneke JA, Vetto JT, Redman BG, Liu PY, Unger JM, Flaherty LE, Sondak VK. A Phase 2 Trial of Complete Resection for Stage IV Melanoma: Results of Southwest Oncology Group Clinical Trial S9430. Cancer 2011 Mar 31.doi: 10.1002/cncr.26111 [Epub ahead of print] PMID: 21455999
Clark J.I., Moon J., Hutchins L.F., Sosman J.A., Kast W.M, Da Silva D.M., Liu P.Y., Thompson J.A., Flaherty L.E., Sondak V.K. Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508. Cancer 116(2)424-31, 2010 PMID: 19918923
Atkins, M.B., Hsu, J., Lee S., Cohen G.I., Flaherty, L.E., Sosman, J.A., Sondak V.K., Kirwood J.M. Phase III Trial Comparing Concurrent Biochemotherapy with Cisplatin, Vinblastine, Darcarbazine, Interleuken-2, and Interferon Alfa-2b with Cisplatin, Vinblastine, and Darcarbazine Alone in Patients with Metastatic Malignant Melanoma (E3695): A Trial Coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 26:5748-5754, 2008. PMID: 19001327
Sosman J.A., Carrillo C., Urba W.J., Flaherty L., Atkins M.B., Clark J.I., Dutcher J., Margolin, K.A., Mier J., Gollob J., Kirkwood JM., Panka D.J., et al. Three Phase II Cytokine Working Group Trials of GP 100 (210M) Peptide Plus High-Dose Interleukin-2 in Patients with HLA-A2-Positive Advanced Melanoma. J Clin Oncol 26:2295-2298, 2008 PMID: 18467720
Hutchins L.F., Moon J., Clark J.I., Thompson J.A., Lange M.K., Flaherty L.E., Sondak V.K. Evaluation of interferon alpha-2B and thalidomide in patients with disseminated malignant melanoma, phase 2, SWOG 0026. Cancer 110(10):2269-75, 2007. PMID: 17932881
Thatai L.C., Vishnubhotla P., Biernat L., Flaherty L., LoRusso P., Simon M., Stephens D., Vereeke K., Abrams J., Bouwman D., Philip P.A. A phase II study of docetaxel, doxorubicin, and infusional 5-fluorouracil in the treatment of patients with locally advanced breast cancer. Am J Clin Oncol 2006; 29:484-9.PMID: 17023784
PubMed Database Link: https://pubmed.ncbi.nlm.nih.gov/?term=Lawrence+Flaherty